Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (Suzhou) Co. Ltd.
Explore linked clinical trials.82 results · Page 1 of 4
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, malignant pancreatic neoplasm, neoplasm, pancreas disorder, pancreatic neoplasm | Recruiting | Phase 3 | 2026-10-05 | NCT07066098 | |
| A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis | Acute Gouty Arthritis | Not yet recruiting | Phase 2 | 2026-09-25 | NCT07842497 | |
| IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Locally Advanced Solid Tumor | Recruiting | Phase 1 | 2026-09-25 | NCT06349408 | |
| A Study of IBI3016 in Japanese Participants | cardiovascular disorder, hypertensive disorder, vascular disorder | Recruiting | Phase 1 | 2026-09-24 | NCT07838220 | |
| A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease | Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, arthritic joint disease, arthropathy, autoimmune disease, connective tissue disorder, dry eye syndrome, eye disorder, immune system disorder, lacrimal apparatus disorder, mouth disorder, musculoskeletal system disorder, rheumatic disorder, rheumatoid arthritis, salivary gland disorder | Not yet recruiting | Phase 2 | 2026-09-23 | NCT07836660 | |
| Study of IBI3016 in People With Mild or Moderate Hypertension Patients | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 1 | 2026-09-23 | NCT07556796 | |
| A Dose Finding Study of IBI3016 in Mild to Moderate Hypertensive Patients | cardiovascular disorder, hypertensive disorder, vascular disorder | Active, not recruiting | Phase 2 | 2026-09-22 | NCT07352969 | |
| A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 2 | 2026-09-22 | NCT06862908 | |
| A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | Blood Protein Disorders, Disease Attributes, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Recruiting | Phase 3 | 2026-09-17 | NCT07623798 | |
| IBI3042 Study in Healthy Participants and Overweight or Obese Participants | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Recruiting | Phase 1 | 2026-09-11 | NCT07793019 | |
| A Study of IBI3046 in Participants With Overweight or Obesity | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Not yet recruiting | Phase 1 | 2026-09-09 | NCT07809945 | |
| Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, fallopian tube cancer, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm | Active, not recruiting | Phase 3 | 2026-09-09 | NCT06834672 | |
| Safety, Tolerability and Preliminary Efficacy of IBI363 in Subjects With Advanced Solid Tumors or Lymphoma | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 1 | 2026-08-25 | NCT05460767 | |
| Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, overnutrition | Not yet recruiting | Phase 1 | 2026-08-14 | NCT07765160 | |
| A Open-Label Phase in Participants With Multiple Myeloma | Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease | Not yet recruiting | Phase 2 | 2026-08-14 | NCT07764861 | |
| IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyslipidemias, Lipid Metabolism Disorders, Lipid Metabolism, Inborn Errors, Nutritional and Metabolic Diseases, familial hypercholesterolemia, hereditary disease, hyperlipidemia, hyperlipoproteinemia, inborn errors of metabolism, metabolic disease | Active, not recruiting | Phase 3 | 2026-08-14 | NCT07473960 | |
| A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Eye Diseases, Hereditary, Graves Ophthalmopathy, Graves disease, autoimmune disease, disease of orbital part of eye adnexa, endocrine system disorder, exophthalmos, eye disorder, goiter, hereditary disease, hyperthyroidism, immune system disorder, thyroid gland disorder | Recruiting | Phase 4 | 2026-08-13 | NCT07265258 | |
| Radscopal Radiotherapy Plus Immunotherapy for Chemotherapy-Ineligible Patients With Newly Diagnosed Metastatic Nasopharyngeal Cancer: A Single-Center, Open-Label, Phase II Study | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Otorhinolaryngologic Neoplasms, Pharyngeal Diseases, Stomatognathic Diseases, carcinoma, epithelial neoplasm, nasopharyngeal carcinoma, nasopharyngeal disorder, nasopharyngeal neoplasm, neoplasm, otorhinolaryngologic disease | Not yet recruiting | Phase 2 | 2026-08-10 | NCT07756190 | |
| A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Not yet recruiting | Phase 3 | 2026-08-10 | NCT07754786 | |
| IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal cancer, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-08-10 | NCT07722494 | |
| A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer | IO-resistant sqNSCLC | Recruiting | Phase 3 | 2026-08-04 | NCT07217301 | |
| A Study of IBI363 in Subjects With Advanced Melanoma | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Skin and Connective Tissue Diseases, melanocytic neoplasm, melanoma, neoplasm, neuroendocrine neoplasm, primitive neuroectodermal tumor, skin disorder, skin neoplasm | Recruiting | Phase 2 | 2026-07-29 | NCT06081920 | |
| Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, neoplasm, uterine disorder | Not yet recruiting | Phase 2 | 2026-07-28 | NCT07731607 | |
| IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | Recruiting | Phase 2 | 2026-07-27 | NCT07122687 | |
| Clinical Trials of IBI3035 in Healthy Subjects | Healthy Person | Recruiting | Phase 1 | 2026-07-16 | NCT07591519 |